

USE OF TEVARS FOR TBAD IN PATIENTS WITH
CONNECTIVE TISSUE DISEASE:
WHEN SHOULD THEY BE DONE?
HOW DURABLE ARE THEY?
WHEN ARE OPEN REPAIRS BETTER?


Martin R Back, MD
Professor & Chief
Division of Vascular Surgery
University of Florida, Gainesville FL USA





Introduction


- Open aortic repair (OAR) is the gold standard for connective tissue disease (CTD) patients with aortic pathology.
- CTD patients undergoing OAR have mortality rates of ~5-15% and 5-year survival of ~50-60% even at centers of excellence.
- Clinical guidelines recommend against endovascular aortic repair (EAR) in CTD patients, despite lack of Level I evidence.
- Objective: UF retrospective analysis of outcomes of consecutive EAR in CTD patients 2005 - 2023

















CONCLUSIONS

- Endovascular repair has a selected role in treatment of aortic dissections & aneurysms with CTD patients
- Targeted endovascular repair for higher risk CTD patients, emergent presentations and desc thoracic aorta pathology with TEVAR
- Lower aortic related mortality is achievable but stringent surveillance is needed as secondary interventions are frequent and multiple aortic / branch interventions are expected in CTD patients (total aortic replacement)